FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205282783> ?p ?o ?g. }

• W4205282783 endingPage "e1134" @default.
• W4205282783 startingPage "e1134" @default.
• W4205282783 abstract "Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare, autoimmune demyelinating CNS disorder, distinct from multiple sclerosis and neuromyelitis optica spectrum disorder. Characterized by pathogenic immunoglobulin G (IgG) antibodies against MOG, a potential treatment strategy for MOGAD is to reduce circulating IgG levels, e.g., by interference with the IgG recycling pathway mediated by the neonatal Fc receptor (FcRn). Although the optic nerve is often detrimentally involved in MOGAD, the effect of FcRn blockade on the visual pathway has not been assessed. Our objective was to investigate effects of a monoclonal anti-FcRn antibody in murine MOG-IgG-associated experimental autoimmune encephalomyelitis (EAE).We induced active MOG35-55 EAE in C57Bl/6 mice followed by the application of a monoclonal MOG-IgG (8-18C5) 10 days postimmunization (dpi). Animals were treated with either a specific monoclonal antibody against FcRn (α-FcRn, 4470) or an isotype-matched control IgG on 7, 10, and 13 dpi. Neurologic disability was scored daily on a 10-point scale. Visual acuity was assessed by optomotor reflex. Histopathologic hallmarks of disease were assessed in the spinal cord, optic nerve, and retina. Immune cell infiltration was visualized by immunohistochemistry, demyelination by Luxol fast blue staining and complement deposition and number of retinal ganglion cells by immunofluorescence.In MOG-IgG-augmented MOG35-55 EAE, anti-FcRn treatment significantly attenuated neurologic disability over the course of disease (mean area under the curve and 95% confidence intervals (CIs): α-FcRn [n = 27], 46.02 [37.89-54.15]; isotype IgG [n = 24], 66.75 [59.54-73.96], 3 independent experiments), correlating with reduced amounts of demyelination and macrophage infiltration into the spinal cord. T- and B-cell infiltration and complement deposition remained unchanged. Compared with isotype, anti-FcRn treatment prevented reduction of visual acuity over the course of disease (median cycles/degree and interquartile range: α-FcRn [n = 16], 0.50 [0.48-0.55] to 0.50 [0.48-0.58]; isotype IgG [n = 17], 0.50 [0.49-0.54] to 0.45 [0.39-0.51]).We show preserved optomotor response and ameliorated course of disease after anti-FcRn treatment in an experimental model using a monoclonal MOG-IgG to mimic MOGAD. Selectively targeting FcRn might represent a promising therapeutic approach in MOGAD." @default.
• W4205282783 created "2022-01-26" @default.
• W4205282783 creator A5004962277 @default.
• W4205282783 creator A5005139311 @default.
• W4205282783 creator A5012468183 @default.
• W4205282783 creator A5014862228 @default.
• W4205282783 creator A5026323738 @default.
• W4205282783 creator A5026430936 @default.
• W4205282783 creator A5032628316 @default.
• W4205282783 creator A5037249717 @default.
• W4205282783 creator A5041657302 @default.
• W4205282783 creator A5050382011 @default.
• W4205282783 creator A5055760387 @default.
• W4205282783 creator A5064993558 @default.
• W4205282783 creator A5068802667 @default.
• W4205282783 creator A5075788706 @default.
• W4205282783 creator A5084652666 @default.
• W4205282783 creator A5091050492 @default.
• W4205282783 date "2022-01-13" @default.
• W4205282783 modified "2023-09-30" @default.
• W4205282783 title "Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis" @default.
• W4205282783 cites W1503658239 @default.
• W4205282783 cites W1862461292 @default.
• W4205282783 cites W1968234562 @default.
• W4205282783 cites W1998009350 @default.
• W4205282783 cites W2007502293 @default.
• W4205282783 cites W2007668953 @default.
• W4205282783 cites W2009502173 @default.
• W4205282783 cites W2013932229 @default.
• W4205282783 cites W2024627890 @default.
• W4205282783 cites W2071843728 @default.
• W4205282783 cites W2094450831 @default.
• W4205282783 cites W2107604806 @default.
• W4205282783 cites W2126825171 @default.
• W4205282783 cites W2146934536 @default.
• W4205282783 cites W2345985251 @default.
• W4205282783 cites W2591423018 @default.
• W4205282783 cites W2606053766 @default.
• W4205282783 cites W2747647717 @default.
• W4205282783 cites W2765636446 @default.
• W4205282783 cites W2795622288 @default.
• W4205282783 cites W2806973999 @default.
• W4205282783 cites W2884626427 @default.
• W4205282783 cites W2889824173 @default.
• W4205282783 cites W2897656082 @default.
• W4205282783 cites W2899777989 @default.
• W4205282783 cites W2903304066 @default.
• W4205282783 cites W2942131384 @default.
• W4205282783 cites W2943416206 @default.
• W4205282783 cites W2957170417 @default.
• W4205282783 cites W2972221943 @default.
• W4205282783 cites W2982768830 @default.
• W4205282783 cites W2991438804 @default.
• W4205282783 cites W2995726856 @default.
• W4205282783 cites W3001193101 @default.
• W4205282783 cites W3018886418 @default.
• W4205282783 cites W3034095681 @default.
• W4205282783 cites W3036213479 @default.
• W4205282783 cites W3083442625 @default.
• W4205282783 cites W3092600921 @default.
• W4205282783 cites W3100094353 @default.
• W4205282783 cites W3101274966 @default.
• W4205282783 cites W3135867765 @default.
• W4205282783 cites W3161878813 @default.
• W4205282783 cites W3170470841 @default.
• W4205282783 cites W3195674796 @default.
• W4205282783 doi "https://doi.org/10.1212/nxi.0000000000001134" @default.
• W4205282783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35027475" @default.
• W4205282783 hasPublicationYear "2022" @default.
• W4205282783 type Work @default.
• W4205282783 citedByCount "9" @default.
• W4205282783 countsByYear W42052827832022 @default.
• W4205282783 countsByYear W42052827832023 @default.
• W4205282783 crossrefType "journal-article" @default.
• W4205282783 hasAuthorship W4205282783A5004962277 @default.
• W4205282783 hasAuthorship W4205282783A5005139311 @default.
• W4205282783 hasAuthorship W4205282783A5012468183 @default.
• W4205282783 hasAuthorship W4205282783A5014862228 @default.
• W4205282783 hasAuthorship W4205282783A5026323738 @default.
• W4205282783 hasAuthorship W4205282783A5026430936 @default.
• W4205282783 hasAuthorship W4205282783A5032628316 @default.
• W4205282783 hasAuthorship W4205282783A5037249717 @default.
• W4205282783 hasAuthorship W4205282783A5041657302 @default.
• W4205282783 hasAuthorship W4205282783A5050382011 @default.
• W4205282783 hasAuthorship W4205282783A5055760387 @default.
• W4205282783 hasAuthorship W4205282783A5064993558 @default.
• W4205282783 hasAuthorship W4205282783A5068802667 @default.
• W4205282783 hasAuthorship W4205282783A5075788706 @default.
• W4205282783 hasAuthorship W4205282783A5084652666 @default.
• W4205282783 hasAuthorship W4205282783A5091050492 @default.
• W4205282783 hasBestOaLocation W42052827831 @default.
• W4205282783 hasConcept C126322002 @default.
• W4205282783 hasConcept C142724271 @default.
• W4205282783 hasConcept C159654299 @default.
• W4205282783 hasConcept C203014093 @default.
• W4205282783 hasConcept C2776572573 @default.
• W4205282783 hasConcept C2777899865 @default.
• W4205282783 hasConcept C2778486448 @default.

• next